Summary
A Phase I trial of Taxol administered as a 120 h infusion once every 3 weeks was conducted in 20 patients with advanced cancer. The initial dose was 5 mg/m2/d (25 mg/m2 total dose) and patients received 10 mg/m2/d, 25 mg/m2/d, 30 mg/m2/d and 36 mg/m2/d. Forty-four courses of taxol were administered and all patients were evaluable for toxicity. Grade 4 leukopenia was the dose limiting toxicity observed in 50% of patients treated with 36 mg/m2/d. Significant mucositis was also observed at 30 and 36 mg/m2/d. All toxicity resolved within three weeks of treatment and no cumulative toxicity was observed. No neurotoxicity or cardiotoxicity was observed and no episodes of hypersensitivity reaction were noted. We conclude that 30 mg/m2/d is an appropriate dose for phase II testing of this schedule.
Similar content being viewed by others
References
Wani M, Taylor H, Wall M, Coggon P, McPhail A: Plant antitumor agents. VI The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus Brevifolia. J Am Chem Soc 93:2325–2327, 1971
Schiff P, Horowitz S: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565, 1980
Manfredi J, Horowitz S: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 25:83–125, 1984
Keller H, Zimmerman A: Shape changes and chemokinesis of Walker 256 carcinosarcoma cells in response to colchicine, vinblastine, nocodozole and taxol. Invasion Metastasis 6:33–43, 1986
Crossin K, Carney D: Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27:341–350, 1981
McGuire W, Rowinsky E, Rosenshien N, Grumbine F, Ettinger D, Armstrong D, Donehouwer R: Taxol: a novel investigational antimicrotubule agent. Ann Int Med 111: 273–279, 1989
Rowinsky EK, Cazenave LA, Donehower RC: Taxol: a novel investigational antimicrotubule agent. JNCI 82:1247–1259, 1990
Longnecker S, Donehower R, Cates A, Chen T, Brundrett R, Grochow L, Ettinger D, Colvin M: High-performance liquid chromatography for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53–59, 1987
Rowinsky EK, McGuire WP, Guarnieri T, Fisherman J, Christian M, Donehower R: Cardiac disturbances during administration of Taxol. J Clin Oncol 9:1704–1712, 1991
Weiss R, Donehower R, Weirnik P, Ohnuma T, Gralla R, Trump D, Baker J, Van Echo D, Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263–1268, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spriggs, D.R., Tondini, C. Taxol administered as a 120 hour infusion. Invest New Drugs 10, 275–278 (1992). https://doi.org/10.1007/BF00944181
Issue Date:
DOI: https://doi.org/10.1007/BF00944181